Want to see MDGL full AI Analyst Report?
MDGL Stock Chart & Stats
$532.02
-$1.78(-0.55%)
At close: 4:00 PM EST
$532.02
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$286.44 - $615.00
Previous CloseN/A
Volume47.78K
Average Volume (3M)367.65K
Market Cap
$12.91B
Enterprise Value$11.64B
Total Cash (Recent Filing)$817.93M
Total Debt (Recent Filing)$347.31M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 11, 2026EPS Estimate
-2.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.80
Shares Outstanding23,055,658
10 Day Avg. Volume524,549
30 Day Avg. Volume367,649
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue10.28
Enterprise Value/Gross Profit11.04
Enterprise Value/Ebitda-41.41
Forecast
1Y Price Target
$669.06Price Target Upside25.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-7.21
Revenue Forecast (FY)$1.49B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Scale & High Gross MarginsSustained ~$1.1B TTM revenue and ~93% gross margins indicate durable product-level economics. High gross margins create room to absorb commercial and R&D spend and improve operating leverage over time, supporting eventual path to profitability if revenue growth persists.
Blockbuster Sales And Rapid Patient AdoptionRapid patient growth and accelerating sales reflect strong commercial execution, broad prescriber adoption, and payer access. This durable demand base supports scale benefits, deeper real-world evidence, and a rising installed patient population that can sustain revenues as diagnosis and penetration expand.
Material Cash Resources To Fund Growth~$818M in liquidity provides multi-quarter runway to support commercialization, upcoming outcomes trials, and recently in-licensed programs without immediate dilution. This reduces short-term financing pressure and enables continued investment in commercial scale and pipeline execution while revenues ramp.
Bears Say
Negative Operating Cash Flow And Cash BurnPersistent negative operating and free cash flow despite strong sales implies the business is not yet self-funding. Continued cash burn increases reliance on external financing or asset monetization, which can dilute shareholders or constrain strategic optionality if revenue or margin trends weaken.
Near-term Unprofitability And Rising OpexElevated SG&A and R&D spending tied to launch, DTC, and BD deals pushes break-even further out. Structural high operating expenses mean sustained revenue growth must outpace spend to deliver durable profit improvement, raising execution risk if commercial traction slows.
High Gross‑to‑net Discounts And Royalty BurdenSubstantial gross-to-net deductions and royalty payments materially reduce realized revenue and compress net margins. These structural commercial costs lower cash conversion and require significantly higher gross sales to achieve the same net revenue, challenging margin sustainability.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $286.44 and its highest was $615.00 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $12.91B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on May 06, 2026. The company reported -$3.25 earnings per share for the quarter, beating the consensus estimate of -$4.23 by $0.98.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -2.76.
How many shares outstanding does Madrigal have?
Madrigal has 23,055,658 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$3.25 in its last earnings report, beating expectations of -$4.23. Following the earnings report the stock price went up 7.415%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$669.06 (25.76% Upside)
$669.06 (25.76% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 336.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $435.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.47%
12-Months-Change
Fundamentals
Return on Equity
-50.15%
Trailing 12-Months
Asset Growth
23.15%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$669.06
▲(25.76% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
17.97% Insiders
25.19% Mutual Funds
0.59% Other Institutional Investors
44.49% Public Companies and
Individual Investors